A phase 1 study of XL019 a selective JAK2 inhibitor, in patients with primary myelofibrosis and, post-polycythemia vera/essential thrombocythemia myelofibrosis

被引：12

作者：

Verstovsek, Srdan ^{[1
]}

Pardanani, Animesh D. ^{[2
]}

Shah, Neil P. ^{[3
]}

Sokol, Lubomir ^{[4
]}

Wadleigh, Martha ^{[5
]}

Gilliland, D. Gary

List, Alan F. ^{[4
]}

Tefferi, Ayalew ^{[2
]}

Kantarjian, Hagop M. ^{[1
]}

Bui, Lynne A. ^{[6
]}

Clary, Douglas O. ^{[6
]}

机构：

[1] MD Anderson Canc Ctr, San Francisco, CA USA

[2] Mayo Clin, San Francisco, CA USA

[3] Univ Calif San Francisco, San Francisco, CA USA

[4] H Lee Moffitt Canc Ctr & Res Inst, San Francisco, CA USA

[5] Dana Farber Canc Inst, San Francisco, CA USA

[6] Exelixis Inc, San Francisco, CA USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.553.553

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

553

引用

页码：170A / 170A

页数：1

共 50 条

[11] The Evolving Understanding of Prognosis in Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis vs Primary Myelofibrosis
Masarova, Lucia
Verstovsek, Srdan
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 299 - 307
[12] Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/ Essential Thrombocythemia Myelofibrosis
Bewersdorf, Jan Philipp
Verstovsek, Srdan
Derkach, Andriy
Masarova, Lucia
Pemmaraju, Naveen
Stein, Eytan
Mauro, Michael
Rampal, Raajit K.
Bose, Prithviraj
BLOOD, 2022, 140 : 6844 - 6846
[13] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Bewersdorf, Jan P.
Verstovsek, Srdan
Derkach, Andriy
Masarova, Lucia
Pemmaraju, Naveen
Stein, Eytan M.
Mauro, Michael
Rampal, Raajit
Bose, Prithviraj
CANCER RESEARCH, 2023, 83 (08)
[14] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Bewersdorf, Jan Philipp
Verstovsek, Srdan
Derkach, Andriy
Masarova, Lucia
Pemmaraju, Naveen
Stein, Eytan M.
Mauro, Michael J.
Rampal, Raajit
Bose, Prithviraj
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[15] A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Bewersdorf, Jan Philipp
Derkach, Andriy
Masarova, Lucia
Pemmaraju, Naveen
Stein, Eytan M.
Mauro, Michael
Rampal, Raajit K.
Bose, Prithviraj
BLOOD, 2023, 142
[16] Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
Masarova, Lucia
Bose, Prithviraj
Daver, Naval
Pemmaraju, Naveen
Newberry, Kate J.
Manshouri, Taghi
Cortes, Jorge
Kantarjian, Hagop M.
Verstovsek, Srdan
LEUKEMIA RESEARCH, 2017, 59 : 110 - 116
[17] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
Sliwa, Thamer
Beham-Schmid, Christine
Burgstaller, Sonja
Buxhofer-Ausch, Veronika
Gastl, Guenther
Geissler, Klaus
Krauth, Maria
Krippl, Peter
Lang, Alois
Petzer, Andreas
Woehrer, Stefan
Woelfler, Albert
Gisslinger, Heinz
WIENER KLINISCHE WOCHENSCHRIFT, 2017, 129 (9-10) : 293 - 302
[18] A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
Mesa, R. A.
Camoriano, J. K.
Geyer, S. M.
Wu, W.
Kaufmann, S. H.
Rivera, C. E.
Erlichman, C.
Wright, J.
Pardanani, A.
Lasho, T.
Finke, C.
Li, C. Y.
Tefferi, A.
LEUKEMIA, 2007, 21 (09) : 1964 - 1970
[19] A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
R A Mesa
J K Camoriano
S M Geyer
W Wu
S H Kaufmann
C E Rivera
C Erlichman
J Wright
A Pardanani
T Lasho
C Finke
C Y Li
A Tefferi
Leukemia, 2007, 21 : 1964 - 1970
[20] Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement
Thamer Sliwa
Christine Beham-Schmid
Sonja Burgstaller
Veronika Buxhofer-Ausch
Günther Gastl
Klaus Geissler
Maria Krauth
Peter Krippl
Alois Lang
Andreas Petzer
Stefan Wöhrer
Albert Wölfler
Heinz Gisslinger
Wiener klinische Wochenschrift, 2017, 129 : 293 - 302

← 1 2 3 4 5 →